


# MOUNJARO<sup>®</sup> (TIRZEPATIDE): NOW AVAILABLE TO ORDER IN CANADA

Mounjaro is now available to order in Canada. Mounjaro comes in a single use, single dose vial.

- > Syringes, needles, and other injection supplies are NOT included and must be dispensed with Mounjaro.
  - The syringes dispensed should be equipped with a needle appropriate for subcutaneous injection, for example, 0.5 mL insulin syringes with a 6 mm (31G) or 8 mm (30G) needle.
- > Vials should be in the fridge between 2°C to 8°C (do not freeze). If needed, Mounjaro can be stored at room temperature up to 30°C for up to 21 days.

## Dosing Overview for Mounjaro

**START**



**2.5**  
MG/0.5 ML  
PER WEEK

DIN: 02541041  
UPC: 773007001591

Starting dose for 4 weeks  
(not a therapeutic dose)

➔



**5**  
MG/0.5 ML  
PER WEEK

DIN: 02541068  
UPC: 773007001614

For at least  
4 weeks

If additional glycemic control is needed, you can continue to increase the dose by 2.5 mg increments after at least 4 weeks at the current dose.<sup>1</sup>


**Please refer to the Instructions for Use and Product Monograph for complete dosing and administration information.**

**To order Mounjaro, contact your preferred distributor.**

**MORE INFORMATION WILL BE AVAILABLE AT MOUNJARO.CA\***



**INDIVIDUALIZE**




**7.5**  
MG/0.5 ML  
PER WEEK

DIN: 02541076  
UPC: 773007001638

For at least  
4 weeks

➔




**10**  
MG/0.5 ML  
PER WEEK

DIN: 02541084  
UPC: 773007001652

For at least  
4 weeks

➔




**12.5**  
MG/0.5 ML  
PER WEEK

DIN: 02541092  
UPC: 773007001676

For at least  
4 weeks

➔



**15**  
MG/0.5 ML  
PER WEEK

DIN: 02541106  
UPC: 773007001690

Maximum  
dose

Mounjaro (tirzepatide injection) is indicated for once-weekly administration as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus.<sup>1</sup>

- As **monotherapy** when metformin is inappropriate due to contraindication or intolerance.
- In **combination with**:
  - > metformin, or
  - > metformin and a sulfonylurea, or
  - > metformin and a sodium-glucose cotransporter 2 inhibitor (SGLT2i), or
  - > basal insulin with or without metformin

Please consult the Product Monograph at <http://pi.lilly.com/ca/mounjaro-ca-pm.pdf> for more information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use which have not been discussed in this advertisement. The Product Monograph is also available by calling us at 1-888-545-5972.

\*Mounjaro.ca home page is open to the general public. To access healthcare provider-directed information, you will need to log in.

Reference: 1. Current Mounjaro Product Monograph. Eli Lilly Canada Inc.



PP-TR-CA-0069 10/2023 © 2023, Eli Lilly and Company. All rights reserved.  
Mounjaro<sup>®</sup> is a registered trademark owned by or licensed to Eli Lilly and Company, its subsidiaries or affiliates.

